These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 34216297)
41. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay. Galassi G; Marchioni A Acta Neurol Belg; 2021 Jun; 121(3):633-642. PubMed ID: 33811309 [TBL] [Abstract][Full Text] [Related]
42. Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. Aschman T; Schneider J; Greuel S; Meinhardt J; Streit S; Goebel HH; Büttnerova I; Elezkurtaj S; Scheibe F; Radke J; Meisel C; Drosten C; Radbruch H; Heppner FL; Corman VM; Stenzel W JAMA Neurol; 2021 Aug; 78(8):948-960. PubMed ID: 34115106 [TBL] [Abstract][Full Text] [Related]
43. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. Kurtzman DJB; Vleugels RA J Am Acad Dermatol; 2018 Apr; 78(4):776-785. PubMed ID: 29229575 [TBL] [Abstract][Full Text] [Related]
44. High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies. Bae SS; Lee YY; Shahbazian A; Wang J; Meriwether D; Golub I; Oganesian B; Dowd T; Reddy ST; Charles-Schoeman C Rheumatology (Oxford); 2020 Nov; 59(11):3515-3525. PubMed ID: 32830270 [TBL] [Abstract][Full Text] [Related]
45. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Lotfi R; Kalmarzi RN; Roghani SA Immunol Res; 2021 Jun; 69(3):213-224. PubMed ID: 33928531 [TBL] [Abstract][Full Text] [Related]
46. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Syrmou V; Liaskos C; Ntavari N; Mitsimponas K; Simopoulou T; Alexiou I; Vlychou M; Katsiari CG; Bogdanos DP Immunol Res; 2023 Aug; 71(4):537-546. PubMed ID: 36928720 [TBL] [Abstract][Full Text] [Related]
47. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567 [TBL] [Abstract][Full Text] [Related]
48. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Ono N; Kai K; Maruyama A; Sakai M; Sadanaga Y; Koarada S; Inoue T; Tada Y Rheumatology (Oxford); 2019 May; 58(5):786-791. PubMed ID: 30541137 [TBL] [Abstract][Full Text] [Related]
49. Role of cytokines and chemokines in idiopathic inflammatory myopathies. De Paepe B; Creus KK; De Bleecker JL Curr Opin Rheumatol; 2009 Nov; 21(6):610-6. PubMed ID: 19726994 [TBL] [Abstract][Full Text] [Related]
50. [Antibodies in dermatomyositis and other inflammatory myopathies: what the dermatologist must know]. Hüe S; Ingen-Housz-Oro S; Fardet L Ann Dermatol Venereol; 2015 Feb; 142(2):149-54. PubMed ID: 25582572 [No Abstract] [Full Text] [Related]
51. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report. De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518 [TBL] [Abstract][Full Text] [Related]
52. Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. Sabbagh SE; Neely J; Chow A; DeGuzman M; Lai J; Lvovich S; McGrath T; Pereira M; Pinal-Fernandez I; Roberts J; Rouster-Stevens K; Schmeling H; Sura A; Tarshish G; Tucker L; Rider LG; Kim S; Rheumatology (Oxford); 2021 Feb; 60(2):829-836. PubMed ID: 32889531 [TBL] [Abstract][Full Text] [Related]
53. A case of Anti-MDA5-Positive dermatomyositis after inactivated COVID-19 vaccine. Yang L; Ye T; Liu H; Huang C; Tian W; Cai Y J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e127-e129. PubMed ID: 36222733 [No Abstract] [Full Text] [Related]
54. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894 [TBL] [Abstract][Full Text] [Related]
55. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977 [TBL] [Abstract][Full Text] [Related]
56. Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection. Hannah JR; Ali SS; Nagra D; Adas MA; Buazon AD; Galloway JB; Gordon PA Clin Exp Rheumatol; 2022 Feb; 40(2):329-338. PubMed ID: 35225218 [TBL] [Abstract][Full Text] [Related]
57. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Pinal-Fernandez I; Mecoli CA; Casal-Dominguez M; Pak K; Hosono Y; Huapaya J; Huang W; Albayda J; Tiniakou E; Paik JJ; Johnson C; Danoff SK; Corse AM; Christopher-Stine L; Mammen AL Neurology; 2019 Nov; 93(19):e1768-e1777. PubMed ID: 31594859 [TBL] [Abstract][Full Text] [Related]
58. [New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis]. Váncsa A; Dankó K Orv Hetil; 2016 Jul; 157(30):1179-84. PubMed ID: 27452067 [TBL] [Abstract][Full Text] [Related]
59. Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis. Mandel DE; Malemud CJ; Askari AD Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524083 [TBL] [Abstract][Full Text] [Related]
60. Rhabdomyolysis Following Recovery from Severe COVID-19: A Case Report. Byler J; Harrison R; Fell LL Am J Case Rep; 2021 May; 22():e931616. PubMed ID: 33963170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]